©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Enhanced Expression of the Eosinophil-derived Neurotoxin Ribonuclease (RNS2) Gene Requires Interaction between the Promoter and Intron (*)

(Received for publication, June 14, 1995; and in revised form, March 12, 1996 )

H. Lee Tiffany (1) (2)(§) Jeffrey S. Handen (1) Helene F. Rosenberg (1)(¶)

From the  (1)Laboratory of Host Defenses, NIAID, National Institutes of Health, Bethesda, Maryland, 20892 and the (2)Graduate Genetics Program, George Washington University, Washington, D. C. 20052

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The eosinophil-derived neurotoxin (EDN/RNS2) is a member of the mammalian ribonuclease gene family and is one of four proteins found in the large specific granules of human eosinophilic leukocytes. The gene encoding EDN consists of two exons, including a noncoding exon 1, separated by a single intron from the coding sequence in exon 2. We have identified a functional promoter of the EDN gene and shown that optimal expression depends on interaction between the promoter and one or more sequence elements found in the single intron. Cells of the clone 15 eosinophilic variant of the human promyelocytic HL-60 cell line were transfected with constructs that included the promoter region of the EDN gene alone, promoter with exon 1, and promoter with both exon 1 and the intron positioned 5` to the chloramphenicol acetyltransferase (CAT) reporter gene (constructs referred to as PrCAT, PrExCAT, and PrExInCAT, respectively). Although reporter gene activity from either PrCAT or PrExCAT was only 2-3 fold higher than baseline (CAT alone), inclusion of the single intron (PrExInCAT) resulted in a 28-fold increase in reporter gene activity in uninduced clone 15 cells, and an 80-fold in activity when clone 15 cells were induced to differentiate toward eosinophils with butyric acid. The intron-mediated enhancer activity was reproduced in other human hematopoietic cell lines (K562, Jurkat, U937, and HL-60), but was not found in human 293 kidney cells, suggesting that the function of the enhancer element(s) may be tissue-specific. A significant portion of the observed enhancer activity resides in the first 60 base pairs the the intron, which includes consensus binding sites for both AP-1 and NF-ATp transcription factors, and a 15-base pair segment that is identical to a sequence found in the promoter of the gene encoding the neutrophil granule protein, lactoferrin. The noncoding exon 1/single intron/coding exon 2 genomic structure is a common feature among the mammalian ribonucleases; this finding suggests the possibility of a conserved mechanism of regulation in this gene family.


INTRODUCTION

The regulation of gene expression is critical to the development of cells and organisms. Although the regulation of gene expression during hematopoeisis has been under intense scrutiny, few studies have examined the eosinophil lineage directly. Whereas the regulatory regions of several eosinophil genes have been characterized(1, 2, 3, 4) , the specific molecular events underlying commitment to and differentiation of the eosinophil lineage remain unknown.

The eosinophil-derived neurotoxin (EDN) (^1)is a small, cationic granule protein synthesized during the promyelocyte stage of eosinophil development(5, 6) . The cDNA sequence and complete open reading frame identified EDN as a member of the ribonuclease gene family(7, 8) . The gene encoding EDN (1.2 kilobases, designated RNS2) contains two exons separated by a 230-bp intron, with the entire coding sequence residing on exon 2(9) . This gene structure (noncoding exon 1/single intron/coding exon 2) is shared by least three additional ribonuclease genes, including eosinophil cationic protein (ECP)(9) , angiogenin(10, 11) , and pancreatic ribonuclease(12, 13) , and appears to be a consistent feature of this gene family.

The studies to be described were performed by transfection of various segments of the EDN gene into clone 15 cells; clone 15 is a subline of the human promyelocytic leukemia cell line, HL-60, which was isolated on the the basis of its propensity to develop into cells resembling mature eosinophils(14) . Features of this cell line include formation of Luxol-fast blue staining granules(14, 15) , biosynthesis of eosinophil major basic protein and eosinophil peroxidase(15) , and the ability to express cell surface receptors for interleukin-5(16, 17) . Most recently, we have shown that differentiated clone 15 cells also synthesize immunoreactive ECP and EDN(18) .

In the work presented here, we have identified features within the EDN gene that are responsible for promoting gene expression in human cell lines, including at least one functional enhancer element within the characteristic single intron.


EXPERIMENTAL PROCEDURES

Cell Lines

The human cell lines used in this investigation were obtained from the American Type Tissue Culture Collection (Rockville, MD) and maintained as indicated. The HL-60, (promyelocytic leukemia), U937, (histocytic lymphoma), Jurkat, (acute T cell leukemia), and K562 (chronic myelogenous leukemia) were all grown in RPMI 1640 medium (Biofluids, Inc., Rockville, MD) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone Laboratories, Inc. Logan, Utah or Life Technologies, Inc.), 2 mML-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin at pH 7.2. The HL-60 clone 15 promyelocytic leukemia cells were grown in the same medium supplemented with 25 mM HEPPSO (Sigma) to maintain the pH at 7.6. The human 293 cells, a transformed primary embryonal kidney cell line, were grown in Dulbecco's modified Eagle's medium (Biofluids, Inc.) supplemented as above. All cells were grown at 37 °C and 5% carbon dioxide in a humidified incubator.

Cellular Differentiation

The clone 15 cells were induced to differentiate toward the eosinophil lineage with the addition of 0.5 mM butyric acid (BA) (Sigma) to freshly cultured cells at a concentration of 0.5 times 10^6 cells/ml as described by Fischkoff and colleagues(16, 17) .

RNA Isolation and Northern Analysis

Total RNA was isolated at times indicated using the method of Chirgwin et al.(19) or using an RNA Isolation Kit (Stratagene, La Jolla, CA). Isolated RNA (15 µg/lane) was electrophoresed in a 1% agarose gel containing 2% formaldehyde in 10 mM MOPS buffer, 5 mM sodium acetate, and 1 mM EDTA at pH 7.0. After electrophoresis, RNA was transferred overnight to a Hybond-N nylon filter (Amersham Corp.), UV-cross-linked using a Stratalinker (Stratagene), and probed with the following gene-specific antisense oligonucleotide sequences: (a) EDN, 5`-GTGACAATTTTTGCGACTTTTGTTACTAGGACAGGTCATATTTGGGT-3`, corresponding to bases 341-296 of EDN cDNA(7) ; (b) ECP, 5`-TGCCCGCATTGCAATGGTGCATCGAGGGGGGTTCAGACT-3`, corresponding to bases 222-184 of ECP cDNA(20) ; and (c) human beta-actin, 5`-GCACATGCCGGAGCCGTTGTCGACGACGAGCGCGGCGATATCATCATC-3`, corresponding to amino acids 16-2 encoded by human beta actin(21) . Fifty na nograms of each oligonucleotide probe were radiolabeled using T4 polynucleotide kinase (New England Biolabs, Inc., Beverly, MA) and [-P]ATP (5000Ci/mmol, ICN, San Diego, CA) and purifed on size exclusion columns (Stratagene). Nylon filters containing RNA were prehybridized (40% formamide, 10% dextran sulfate, 4 times SSC, 20 mM Tris, pH 7.5, 1 times Denhardt's solution, 0.1% sodium dodecyl sulfate, and 20 µg/ml denatured salmon sperm DNA) at 38 °C for 1 h. Radiolabeled oligonucleotide was added (2 times 10^6 cpm/ml), and the filters were hybridized at 38 °C for 8 h. The hybridized filters were washed with 2 times SSC and 0.5% SDS twice at 42 °C and twice at 55 °C for 30 min each. Quantitation was performed by densitometric scanning using a Gel Documentation System (UVP, San Gabriel, CA) monitor to image autoradiograms from the Northern blots, followed by analysis with the NIH Image software package.

Primer Extension

Total RNA harvested from clone 15 cells induced to differentiate with BA for 48 h was used for primer extension experiments. Messenger RNA was purified by polyadenosine selection using a Poly(A) Quik Kit (Stratagene) following the manufacturer's procedure. Poly(A)-selected mRNA was then used in primer extension experiments with the Primer Extension System (Promega Corporation, Madison, WI). RNA (EDN mRNA or kanamycin-positive kit control) was reverse transcribed using avian myeloblastosis virus-reverse transcriptase and an antisense EDN-specific primer, EDN-1a (see Fig. 1B), corresponding to nucleotides 192 to 175 (5`-TTGCTGGGAGGTCATATT-3`) of the EDN cDNA(7) . EDN-1a was end-labeled with [-P]ATP (ICN, Costa Mesa, CA) and annealed to the poly(A) selected mRNA prior to reverse transcription. The primer extension reaction was electrophoresed in a denaturing 6% TBE polyacrylamide gel along with known DNA sequence for size determination. The number of nucleotides from the primer to the 5` end of the mRNA was determined.


Figure 1: A, Northern analysis of RNA isolated from the clone 15 eosinophilic variant of HL-60 grown for 0-5 days in the absence (lanes 1-6) or the presence (lanes 7-12) of 0.5 mM BA. Total RNA (10 µg/lane) was probed with a radiolabeled EDN-specific oligonucleotide (see ``Experimental Procedures''); identical samples were probed with a radiolabeled human beta-actin-specific oligonucleotide (see ``Experimental Procedures'') to demonstrate loading of each lane. B, structural schematic of the EDN gene(9) . Transcribed sequences are shown as boxes. The black area depicts the open reading frame; the shaded areas represent untranslated transcript as previously documented by cDNA cloning(7, 8) ; the unshaded area indicates additional transcript demonstrated by primer extension and RACE (see C and D). Below, schematic depicting placement of oligonucleotide primers used in primer extension (EDN-1a) and RACE (EDN-2a and EDN) experiments as described under ``Experimental Procedures.'' C, primer extension from EDN-1a (see B) from mRNA isolated from clone 15 cells induced for 2 days with 0.5 mM BA (A, lane 9) (EDN mRNA) and from control RNA; the + and - symbols indicate reactions performed with or without the addition of mRNA prior to reverse transcription. The primer extension product in the +EDN mRNA lane is indicated by the arrow; its migration relative to the flanking sequence standards (Std) indicates a 219-bp product, extending the known transcript size by 25 bp. D, sequence of the extended transcript isolated by the RACE procedure. Regions of known sequence are as designated (Anchor, Exon 1, Exon 2, and the ATG codon at the start of translation). Short arrows designate the sequence of the 25-bp extension to exon 1.



Rapid Amplification of cDNA Ends

To determine the precise transcriptional start site, rapid amplification of cDNA ends (RACE) was performed using mRNA described above with the 5`-AmpliFINDER(TM) RACE Kit (Clontech Laboratories, Inc., Palo Alto, CA) following the manufacturer's protocol. The cDNA was first synthesized from mRNA using avian myeloblastosis virus-reverse transcriptase and antisense EDN-specific primers. These primers corresponded to nucleotides 291-274, 5`-ACAAACATTAACTACGTT (EDN-2a) of the EDN probe, nucleotides 341-296, described above, of the EDN cDNA sequence(7) . An anchor of known sequence was ligated to the 5` end of the cDNA. Polymerase chain reaction (PCR) amplification (described below) of the anchor ligated cDNA was performed using the supplied anchor primer and a nested primer for each of the antisense EDN primers used to synthesize the cDNA. The nested primer used with the antisense oligonucleotide EDN was EDN-2a, and for EDN-2a the nested primer was EDN-1a, as shown in Fig. 1B. The PCR were performed in a Perkin-Elmer Gene Amp PCR System 9600 using Taq DNA polymerase (5 units) (Boehringer Mannheim) in 10 mM Tris, pH 8.3, buffer containing 50 mM KCl, 2.5 mM MgCl(2), 2 uM each dATP, dCTP, dGTP, and dTTP, 100 ng of each oligonucleotide primer, and 10-50 ng of DNA template. The DNA was denatured for 3 min at 95 °C, followed by a three-step PCR reaction: denaturation at 95 °C for 30 s, annealing at an appropriate temperature for each primer pair for 30 s, and extension at 72 °C for 1 min. After 35 cycles the reactions were extended for an additional 5 min at 72 °C followed by cooling to 4 °C. PCR products were subcloned into pBluescript (Invitrogen, San Diego, CA) for dideoxy sequence analysis.

Isolation of Genomic Clones

EDN genomic clones were isolated from a human lymphocyte genomic library (Clontech Laboratories, Inc.) by plaque hybridization with an EDN cDNA radiolabeled probe (7) and confirmed by dot blotting with the EDN-1a oligonucleotide (see Fig. 1B) and by dideoxy sequencing. The nucleotide sequence obtained agreed with previously published data (9) .

Reporter Gene Constructs

The reporter gene used in these studies was chloramphenicol acetyltransferase (CAT) as found in the pCAT-basic expression vector (Promega). Various fragments of the 5` putative promoter region of EDN both with and without additional intron and/or exon sequence were amplified using the following primers (numbered as per (9) ): 1, 5`-CTGCAGGCAGCATATAGTTTTCAT-3`, nucleotides -312 to -288; 2, 5`-GGTCTCCCCTACTTGGAACT-3`, nucleotides -26 to -45; 3, 5`-CTGTAAGAAAAGAAGAGAAGTAAC-3`, nucleotides 172-149; 4, 5`-CCAGTCTCCGCGCTGTAGC-3`, nucleotides 42-23; 5, 5`-GTAAGTCAACGATCCCCA-3`, nucleotides 43-60; 6, 5`-CCCTCAGTTGCTGCCCCATTG-3`, nucleotides 102-82; 7, 5`-CTTTACTTCCTGTCTGCAAAG-3`, nucleotides 162-142; 8, 5`-ACACACACTGTAGTGTCTTAC, nucleotides 222-202. These primers also contained 5` PstI or XbaI sites as indicated to facilitate subcloning into the pCAT vectors. For the construct containing promoter plus intron, without exon 1, the primers used were 1 and 9 (nucleotides -26 to -45 with a 5` XhoI site to amplify the promoter region). The primers 10 (nucleotides 43-60 with a 5` XhoI site) and 3 were used to amplify the intron sequence. This produced a promoter construct with a XhoI site at its 3` and an intron construct with the XhoI site at its 5` end after PCR amplification. The products were gel purified, restriction digested with XhoI, and ligated; the ligation was followed by a second round of PCR amplification using primers 1 and 3 described above. The 520-bp fragment was gel purified and ligated into the pCAT-basic vector. All constructs were confirmed by dideoxy sequencing.

Electroporation of CAT Constructs into Human Cell Lines

Cell lines as described above were grown to a density of 0.5 to 1.0 times 10^6 cells/ml. Cells were harvested by centrifugation at 2000 rpm for 5 min and resuspended to 30 times 10^6 cells/ml in complete medium as described above for each cell line. Ten to twenty micrograms uncut purified plasmid DNA (using either Qiagen or Promega Maxiprep kit followed by phenol/chloroform extraction) were added to an electroporation cuvette with a 0.4 cm electrode gap (Bio-Rad) with 15 times 10^6 cells. The cells were electroporated at a capacitance of 960 microfarads at 250 volts using a Gene Pulser (Bio-Rad). The cells were placed on ice for 15 min prior to the addition to 30 ml of complete medium and incubated for 2 days at 37 °C, 5% CO(2) in a humidified incubator. Cells were also electroporated with either 10 µg of uncut control pSV-beta-galactosidase (Promega) or pCMV-beta-galactosidase (Stratagene) vector to control for variation in electroporation efficiency. The level of beta-galactosidase activity was determined spectrophotometrically (beta-galactosidase assay kit, Promega). CAT activity was normalized to the level of expression of this control vector.

CAT Assays

CAT assays were performed essentially as described(22) . Transfected cells were harvested after 2 days of incubation by centrifugation at 2000 rpm for 5 min, washed twice at room temperature with phosphate-buffered saline, and resuspended in 0.5 ml of 40 mM Tris, pH 7.4, with 1 mM EDTA and 150 mM NaCl. Cells were then harvested by a 1-min centrifugation in a microfuge and resuspended in 100-150 µl of 25 mM Tris, pH 8, and disrupted by freeze/thaw, three times on dry ice/37 °C water bath. The debris was removed by centrifugation; clarified extract was added to the following reaction mixture: 5-45 µl of extract, 35 µl of 1 M Tris, pH 7.5, 20 µl of 4 mM acetyl Coenzyme A (Pharmacia Biotech Inc.), and 3-5 µl of [^14C]chloramphenicol (0.25 µCi, DuPont NEN), with distilled H(2)O added to a final volume of 150 µl. After 6-12 h at 37 °C, the [^14C]chloramphenicol and acetylated products were extracted by vortexing for 30 s with 1 ml of ethyl acetate. The ethyl acetate layer (upper) was removed and air dried under a hood or SpeedVac (Savant), resuspended in 30 µl of ethyl acetate, and applied to a flexible thin layer chromatography sheet (Baker-flex silica gel 1B, J. T. Baker Inc., Phillipsburg, NJ). Separation of acetylated and nonacetylated forms proceeded via a chloroform/methanol (95:5) ascending mobile phase followed by autoradiography. The signals in each lane of the autoradiogram, including all acetylated forms of chloramphenicol, were measured with a System 200 Image Scanner (Bioscan, Inc., Washington, D. C.).

Analysis of Intronic Region

Computer analysis of the intronic regions of the EDN gene for consensus transcription factor binding sites was performed using the MacVector sequence analysis program. Comparison of intronic regions with known sequences was performed using the FASTA algorithm of the Wisconsin Genetics Computer Group program on-line at the National Institutes of Health.

Sequence Mutations

Specific point mutations were introduced into PrExIn by overlapping PCR mutagenesis (23) using the following oligonucleotide primer pairs along with primers 1 and 8 as described previously: lfn X (5` primer, 5`-TCAACGATCCCCTGTGGTCGCAGACAAGGGGCAGCAAT-3`, and 3` primer, 5`-ATTGCTGCCCCTTGTCTGCGACCACAGGGGATCGTTGA-3`) and lfn Y (5` primer, 5`-TCAACGATCCCCAGTCGACCCACAGAAGGGGCAGCAAT-3`, and 3` primer, 5`-ATTGCTGCCCCTTCTGTGGGTCGACTGGGGATCGTTGA-3`). The altered sequences were subcloned into pCAT basic as described. All mutations were confirmed by dideoxy sequencing.


RESULTS

RNA Expression in the Clone 15 Cell Line

Expression of mRNA for the EDN in the clone 15 cell line is demonstrated in Fig. 1A. Messenger RNA encoding EDN was detected in uninduced clone 15 cells (lanes 1-7); the level of mRNA accumulating in these cells increased 6-7-fold within 48 h after the addition of 0.5 mM BA (lane 9) as determined by densitometric analysis. Hybridization with a beta-actin probe (below) demonstrated relative loading of each lane.

Primer Extension

Primer extension experiments were undertaken to determine the precise location of the transcriptional start site. RNA from clone 15 cells induced for 2 days with 0.5 mM BA was used for this analysis; a control RNA reaction was included, as was a known DNA sequence for determination of molecular size (Fig. 1C). The band in the +EDN mRNA lane indicated by the arrowhead is the reverse-transcribed product. Comparison of the nucleotides in the known sequence (Std) with the mobility of the band indicated in the +EDN mRNA lane demonstrates that the distance from the primer to the 5` end of EDN is 219 nucleotides. This result suggests that there are 25 additional nucleotides in the mRNA sequence that had not previously been identified by cDNA cloning(7, 8) .

Rapid Amplification of cDNA Ends

It was unclear as to whether these additional 25 nucleotides represented a direct extension of exon 1 or a completely distinct exon; RACE was undertaken to make this determination. Using the poly(A)-selected mRNA described for the primer extension experiments, a cDNA strand complementary to the 5` region of the EDN mRNA was reverse transcribed using the EDN or EDN-2a primers (Fig. 1B), PCR amplified, and subcloned. Numerous colonies were obtained; 18 random colonies were selected for sequencing. The results from a representative sequence are depicted in Fig. 1D. The additional 25-base pair sequence obtained, which follows the anchor sequence and precedes the first exon sequence, is 5`-AGCTGCCCCTGAACCCCAGAACAAC-3`. This sequence matches the published genomic sequence of Hamann and colleagues (9) that is found immediately 5` to the previously designated exon 1. These results suggest that the additional nucleotides represent a direct extension of exon 1 as opposed to another distinct exon. The transcriptional start site defined by both primer extension and RACE is located 25 nucleotides 3` from a consensus TATA box(9) . Of the 18 clones, 11 sequences were as described in Fig. 1D, two were 4 nucleotides shorter at the 5` end, and five contained unidentified sequences between the PCR primers. The five unidentified clones are assumed to be the result of incorrect priming, because they contained no sequences representing either exon 1 or exon 2.

CAT Activity in Clone 15 Cells

The sequence of the EDN gene positioned 5` to CAT used in the following experiments are shown in Fig. 2A. The EDN promoter region alone (PrCAT) supported a relatively low level of activity in clone 15 cells, representing 2-3-fold over that of the promotorless CAT (Fig. 2B). Surprisingly, the EDN promoter-exon-intron construct (PrExInCAT) supported significantly greater degree of reporter gene activity: 28-fold over CAT in uninduced clone 15 cells and 80-fold over CAT in clone 15 cells grown in the presence of BA (Fig. 2, B and C). The EDN promoter-exon (PrExCAT) construct produced low levels of CAT activity, similar to those of PrCAT alone, suggesting that the dramatic enhancement seen with PrExInCAT was due to sequence elements found in the intron. The intron alone (InCAT) did not demonstrate reporter gene activity above the basal levels in these cells, whereas the EDN promoter-intron combination (PrInCAT) without the first exon provided a 12-fold increase in activity over CAT alone. The increase in activity with promoter and intron and the absence of activity with the intron alone suggests that the enhanced activity depends on interactions between sequence elements in both the promoter and intron.


Figure 2: A, segments of the EDN gene positioned 5` to the CAT reporter gene: Pr, 287 bp of the 5` promoter region; PrEx, the promoter region and exon 1; PrExIn, promoter region, exon 1, and single intron; Pr+In, promoter and intron without exon 1; In, intron alone. B, reporter gene activity of each CAT construct transfected into clone 15 cells, relative to that of CAT alone (no promoter). The bars represent densitometric analysis of duplicate samples. C, same as B with the addition of 0.5 mM BA to cells immediately after transfection. D, sample autoradiogram depicting CAT activity of constructs transfected into undifferentiated clone 15 cells.



Expression of EDN-CAT Constructs in Other Cell Lines

Analysis of CAT activity in several other cell lines is shown in Fig. 3. PrExInCAT was capable of promoting reporter gene activity 20-40-fold over that observed with the CAT in the K562, Jurkat, U-937, and HL-60 human hematopoietic cell lines (Fig. 3). The EDN promoter alone (PrCAT) supported only the lower, basal levels of expression in all cell lines tested. To evaluate regulation in a nonhematopoietic cell line, the PrCAT and PrExInCAT constructs were introduced into the human transformed 293 kidney cell line. Similar to the observations made with the hematopoietic cells, PrCAT induced a basal (2-3-fold) increase in reporter gene activity over CAT in the human kidney cell line. Interestingly, in contrast to the 20-40-fold increase in activity observed in hematopoietic cells, PrExInCAT induced only a 3-fold increase in the kidney cells. This activity was not significantly greater than that induced by PrCAT, suggesting that the enhancer activity provided by the intron may function in a tissue-specific fashion.


Figure 3: Reporter gene activity of constructs transfected into four distinct human hematopoietic cell lines (HL-60 (promyelocytic leukemia), K562 (chronic myelogenous leukemia), U-937 (histocytic lymphoma), and Jurkat (T cell leukemia)) and one nonhematopoietic human cell line (293 kidney cell). The constructs and quantitation were as described for Fig. 2.



Dissection and Analysis of the Intron

In order to define the region or regions of the intron that enhance gene expression, truncated promoter-intron constructs were evaluated in clone 15 cells (Fig. 4). The PrEx0.25InCAT and PrEx0.5InCAT constructs, which contain the first 60 and first 120 base pairs of the intron, respectively, were both found to increase reporter gene activity 8-fold over CAT alone. These results suggest that there are one or more functional enhancer elements in the first 60 base pairs of the intron. In contrast, the PrEx0.75InCAT construct, containing the first 180 bp of the intron, produces only a 2.5-fold increase in activity over CAT, suggesting that this region (120 and 180 bp) contains sequence elements that neutralize the effects of the aforementioned functional enhancer(s). Full activity (28-fold over CAT) is restored with the complete intron (PrExInCAT), suggesting the possibility of additional functional enhancers in this final segment of the intron.


Figure 4: A, the EDN promoter, exon 1, and truncated versions of the single intron to be positioned 5` to CAT: PrExInCAT, complete (230 bp) intron; PrEx0.25In, first 60 bp of the intron; PrEx0.5In, first 120 bp of the intron; PrEx0.75In, first 180 bp of the intron. B, reporter gene activity of each construct transfected into clone 15 cells, relative to that of CAT (no promoter). The bars represent densitometric analysis of duplicate samples.



A sequence map of the EDN gene with a focus on the intron is shown in Fig. 5A. The first 60 bp of the intron contain consensus binding sites for both AP-1 and NF-ATp transcription factors. In addition, there is a segment of 15 bp that is identical to a segment found in the promoter of the lactoferrin gene (see ``Discussion'')(24) . Point mutations were introduced into the sequence of this segment (Fig. 5B), and the PrExInCAT constructs both with and without mutations were evaluated for their ability to support reporter gene activity. Neither set of mutations (lfn X or lfn Y; Fig. 5, B and C) altered the intron-enhancing activity to any significant degree (21- and 35-fold over CAT alone, as compared with 28-fold for the wild type).


Figure 5: A, nucleotide sequence of the 5` promoter (-287 to -1), exon 1 (1-67), intron (68-297) and the beginning of exon 2 (298 onward). Consensus CAAT and TATA box promoter sequences are as indicated. Consensus transcription factor binding sites (AP-1, NF-ATp, and PU.1) are single overlined; the arrowheads denote the division points for PrExIn0.25CAT, PrEx0.5InCAT, and PrEx0.75InCAT, respectively. The 15-bp segment that is double overlined is identical to a segment found in the 5` promoter region of the neutrophil specific granule protein, lactoferrin(24) . B, mutations introduced into the 15-bp lactoferrin segment in the intron to create lfn X and lfn Y in PrExIn. Points at which lfn X and lfn Y differ from the wild type are indicated over each sequence with filled circles. C, reporter gene activity of each construct transfected into clone 15 cells, relative to that of CAT (no promoter). The bars represent densitometric analysis of duplicate samples.




DISCUSSION

In the initial phase of this study, we determined the transcriptional start site of the EDN gene. Both primer extension and RACE extended the length of the mRNA to include an additional 25 nucleotides. This additional sequence matched the region of genomic sequence that was directly 5` to sequence identified as exon 1(9) . Thus, exon 1 has been enlarged to 67 nucleotides, and the two-exon structure of this gene is confirmed. The transcriptional start site is situated appropriately at 23 and 101 base pairs 3` to consensus TATA and CAAT boxes, respectively.

Although significantly more active than either PrCAT or PrExCAT, we found that PrInCAT was not as effective as PrExInCAT in producing reporter gene activity. It is possible that the noncoding exon 1, in conjunction with the intron, plays a specific role in regulating activity of the EDN gene. However, it is also possible that the spatial rearrangement caused by deletion of this 67-base pair segment affects the ability of promoter and intron binding proteins to interact with one another as they interact with the DNA. This point may be clarified once the binding proteins mediating transcription of the EDN gene have been identified. Furthermore, it is not clear whether the enhancer elements present in the EDN intron coordinate specifically with the EDN promoter, or whether they might function equally effectively with other unrelated gene promoters. Although not completely independent (InCAT produced little reporter gene activity in clone 15 cells), the specificity of the interaction between the intron and the EDN promoter has not been established.

Investigators have been examining the promoter regions of granule protein genes(1, 2, 3, 4, 24, 25) in hopes of identifying factors promoting their tissue-specific expression. Our initial results suggest that the function of one or more of the intronic enhancer elements may be tissue-specific. In contrast to the results obtained with the human hematopoietic cell lines, the PrExInCAT construct supported no additional reporter gene activity over that of the promoter alone (PrCAT) in the human kidney cell line. Although preliminary, the increase in activity of PrExInCAT in the hematopoietic cells but not in the kidney cell line suggests that one or more of the functional enhancer elements may interact with a transcription factor expressed in a limited range of human cell types.

Sequence analysis of the EDN intron revealed the presence of several consensus sequences for transcription factor binding (Fig. 5). In the first 60 bp of the intron, the region in which a large portion of the enhancing activity resides, there are consensus sequences representing binding sites for transcription factors AP-1 (26) and NF-ATp(27) . In addition, a 15-base pair segment that is identical to a sequence found in the 5` promoter region of the neutrophil-specific granule protein, lactoferrin(24) , is highlighted. The coordinate control of eosinophil and neutrophil granule protein biosynthesis was suggested by a series of studies examining the rare genetic disorder known as neutrophil specific granule deficiency(28, 29) . Lomax and colleagues (30) determined that the defective biosynthesis of lactoferrin observed in this disorder resulted from a defect in mRNA transcription affecting specifically cells of the neutrophil lineage. Rosenberg and Gallin (31) showed that the biosynthetic defect could extend to include eosinophils; EDN was among the eosinophil granule proteins affected. Specific mutations introduced into this ``lactoferrin site'' resulted in no significant alteration in reporter gene activity, suggesting that this segment is not crucial to this specific aspect of EDN gene regulation. Additional investigations using electrophoretic mobility shift assays coupled with DNA footprinting and mutational analysis of additional sites will be necessary to determine the source of the enhancing activity.

In summary, this investigation has demonstrated that the intron of the EDN gene contains one or more functional enhancer elements and that interaction between the promoter and these intronic elements is required for the optimal gene expression. Although intronic enhancer elements have been described previously(32, 33, 34, 35, 36, 37, 38, 39) , this is the first evidence that this mechanism exists within the mammalian ribonuclease gene family. This finding takes on considerable significance because the noncoding exon/single intron/coding exon gene structure is shared by all members of this gene family whose gene structures have been determined(9, 10, 11, 12, 13) . Although the nucleotide sequences of introns of each of the characterized ribonuclease genes are not overtly homologous to one another (save for EDN and ECP, whose introns are virtually identical(9) ), the potential for this as a shared mechanism of gene expression is intriguing.


FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
This work was done in partial fulfillment of the requirements for the Ph.D. degree in the Graduate Genetics Dept. of the George Washington University, Washington, D. C.

To whom correspondence should be addressed: Bldg. 10, Rm. 11N104, Laboratory of Host Defenses, NIAID/National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892. Tel.: 301-402-9131; Fax: 301-402-0789; hr2k{at}nih.gov.

(^1)
The abbreviations used are: EDN, eosinophil-derived neurotoxin; ECP, eosinophil cationic protein; bp, base pair(s); CAT, chloramphenicol acetyltransferase; HEPPSO, N-[2-hydroxyethyl]piperazine-N`-[2-hydroxypropanesulfonic acid; BA, butyric acid; MOPS, 3-morpholinepropanesulfonic acid; RACE, rapid amplification of cDNA ends; PCR, polymerase chain reaction.


ACKNOWLEDGEMENTS

We thank Kimberly D. Dyer for providing us with the initial EDN bacteriophage clone and for additional technical assistance and Dr. Sunil K. Ahuja for assistance with the CAT assays. We also thank Dr. Phyllis D. Kind for helpful discussions and Dr. John I. Gallin for continued support of our work.


REFERENCES

  1. Gomolin, H. I., Yamaguchi, Y., Paulpillai, A. V., Dvorak, L. A., Ackerman, S. J., and Tenen, D. G. (1993) Blood 82, 1868-1874 [Abstract]
  2. Yamaguchi, Y., Zhang, D. E., Sun, Z., Albee, E. A., Nagata, S., Tenen, D. G., and Ackerman S. J. (1994) J. Biol. Chem. 269, 19410-19419 [Abstract/Free Full Text]
  3. Li, M. S., Sun, L., Satoh, T., Fisher, L. M., and Spry, C. J. F. (1995) Biochem. J. 305, 921-927 [Medline] [Order article via Infotrieve]
  4. Sun, Z., Yergeau, D. A., Tuypens, T., Tavernier, J., Paul, C. C., Baumann, M. A., Tenen, D. G., and Ackerman, S. J. (1995) J. Biol. Chem. 270, 1462-1471 [Abstract/Free Full Text]
  5. Spry, C. J. F. (1988) Eosinophils: A Comprehensive Review and Guide to the Scientific and Medical Literature , Oxford University Press, Oxford
  6. Bainton, D. F. (1992) in Inflammation: Basic Principles and Clinical Correlates (Gallin, J. I., Goldstein, I. M., and Snyderman, R., eds) 2nd Ed., pp. 303-324, Raven Press, Ltd., New York
  7. Rosenberg, H. F., Tenen, D. G., and Ackerman, S. J. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 4460-4464 [Abstract]
  8. Hamann, K. J., Barker, R. L., Loegering, D. A., and Gleich, G. J. (1989) Gene (Amst.) 83, 161-167
  9. Hamann, K. J., Ten, R. M., Loegering, D. A., Jenkins, R. B., Hiese, M. T., Schad. C. R., Pease, L. R., Gleich, G. J., and Barker, R. L. (1990) Genomics 7, 535-546 [Medline] [Order article via Infotrieve]
  10. Kurachi, K., Davie, E. W., Strydom, D. J., Riordan, J. F., and Vallee, B. L. (1985) Biochemistry 24, 5494-5499 [Medline] [Order article via Infotrieve]
  11. Nakano, T, and Graf, T. (1992) Oncogene 7, 527-534 [Medline] [Order article via Infotrieve]
  12. Samuelson, L. C., Wiebauer, K., Howard, G., Schmid, R. M., Koeplin, D., and Meisler, M. H. (1991) Nucleic Acids Res. 19, 6935-6941 [Medline] [Order article via Infotrieve]
  13. Carsana, A., Confalone, E., Palmieri, M., Libonati, M., and Furia, A. (1988) Nucleic Acids Res. 16, 5491-5502 [Abstract]
  14. Fischkoff, S. A. (1988) Leukemia Res. 12, 679-686 [CrossRef][Medline] [Order article via Infotrieve]
  15. Fischkoff, S. A., Pollak, A., Gleich, G. J., Test, J. R., Misawa, S., and Reber, T. (1984) J. Exp. Med. 60, 179-196
  16. Plaetinck, G., van der Heyden, J., Tavernier, J., Fache, I., Tuypens, T., Fischkoff, S., Fiers, W., and Devos, R. (1990) J. Exp. Med. 172, 683-691 [Abstract]
  17. Tavernier, J., Devos, R., Cornelis, S., Tuypens, T., van der Heyden, J., Fiers, W., and Plaetinck, G. (1991) Cell 66, 1175-1184 [Medline] [Order article via Infotrieve]
  18. Tiffany, H. L., Li, F., and Rosenberg, H. F. (1995) J. Leukocyte Biol. 58, 49-54 [Abstract]
  19. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. (1979) Biochemistry 18, 5294-5299 [Medline] [Order article via Infotrieve]
  20. Rosenberg, H. F., Ackerman, S. J., and Tenen, D. G. (1989) J. Exp. Med. 170, 163-170 [Abstract]
  21. Nakajima-Iyima, S., Hamada, H., Reddy, P., and Kakanaga, T. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 6133-6137 [Abstract]
  22. Ausubel, F., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1995) Short Protocols in Molecular Biology , 3rd Ed., pp. 9.18-9.37, John Wiley & Sons, Inc., New York
  23. Higuchi, R. (1990) in PCR Protocols (Innis, M. A., Gelfand, D. H., Sninsky, J. J., and White, T. J., eds) Chapter 22, Academic Press, San Diego, CA
  24. Johnston, J. J., Rintels, P., Chung, J., Sather, J., Benz, E. J., Jr., and Berliner, N. (1992) Blood 79, 2998-3006 [Abstract]
  25. Pahl, H. L., Scheibe, R. J., Zhang, D. E., Chen, H. M., Galson, D. L., Maki, R. A., and Tenen, D. G. (1993) J. Biol. Chem. 268, 5014-5020 [Abstract/Free Full Text]
  26. Angel, P., Imagawa, M., Chiu, R., Stein, B., Imbra, R. J., Rahmsdorf, H. J., Jonat, C., Herrlich, P., and Karin, M. (1987) Cell 49, 729-739 [Medline] [Order article via Infotrieve]
  27. Rao, A. (1994) Immunology Today 15, 274-281 [CrossRef][Medline] [Order article via Infotrieve]
  28. Gallin, J. I. (1985) Annu. Rev. Med. 36, 263-285 [CrossRef][Medline] [Order article via Infotrieve]
  29. Gallin, J. I., Fletcher, M. P., Seligmann, B. E., Hoffstein, S., Cehrs, K., and Mounessa, N. (1982) Blood 59, 1317-1329 [Abstract]
  30. Lomax, K. J., Gallin, J. I., Rotrosen, D., Raphael, G. D., Kaliner, M. A., Benz, E. J., Boxer, L. A., and Malech, H. L. (1989) J. Clin. Invest. 83, 514-519 [Medline] [Order article via Infotrieve]
  31. Rosenberg, H. F., and Gallin, J. I. (1993) Blood 82, 268-273 [Abstract]
  32. Sawada, S., Scarborough, J. D., Killeen, N., and Littman, D. R. (1994) Cell 77, 917-929 [Medline] [Order article via Infotrieve]
  33. Henkel, G., Weiss, D. L., McCoy, R., Delaughery, T., Tara, D., and Brown, M. A. (1992) J. Immunol. 149, 3239-3246 [Abstract/Free Full Text]
  34. Staudt, L. M., and Lenardo, M. J. (1991) Annu. Rev. Immunol. 9, 373-398 [CrossRef][Medline] [Order article via Infotrieve]
  35. Leiden, J. M. (1993) Annu. Rev. Immunol. 11, 539-570 [CrossRef][Medline] [Order article via Infotrieve]
  36. Bornstein, P., and McKay, J. (1988) J. Biol. Chem. 263, 1603-1606 [Abstract/Free Full Text]
  37. Rippe, R. A., Lorenzen, S.-I., Brenner, D. A., and Breindl, M. (1989) Mol. Cell Biol. 9, 2224-2227 [Medline] [Order article via Infotrieve]
  38. Pogulis, R. J., and Freytag, S. O. (1993) J. Biol. Chem. 268, 2493-2499 [Abstract/Free Full Text]
  39. Tourmente, S., Chapel, S., Dreau, D., Drake, M. E., Bruhat, A., Couderc, J. L., and Dastudue, B. (1993) Insect Biochem. Mol. Biol. 23, 137-143 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.